Editorial Comment

As outlined in this review, adjuvant therapy for locally advanced renal cell carcinoma has remained the elusive holy grail and has been the subject of much research. Unfortunately all prior research had been negative, until recent developments again focused the spotlight on this important endeavor. Two recently completed phase III trials address the question of the role of targeted therapy with tyrosine kinase inhibitors in the adjuvant setting. The ASSURE trial, which examined the benefit of sunitinib or sorafenib vs placebo for 1 year, failed to reveal a benefit in DFS or OS (reference 39 in article).
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Review Article Source Type: research